Home Tags Japan

Tag: Japan

Eisai & Co and Bliss Biopharmaceutical (Hangzhou) Sign Agreement to Jointly...

ADC Review | Editorial Team
Japanese drugmaker Eisai & Co and Chinese drug developer Bliss Biopharmaceutical (Hangzhou) Co., have entered into a joint development agreement to further develop BB-1701, an antibody-drug conjugate (ADC). As part of the agreement Eisai & Co obtained option rights for a strategic collaboration.

DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan’s Ministry of...

Peter Hofland
DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, has received SAKIGAKE Designation for the treatment of HER2-positive advanced gastric...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X